Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zelluna ASAOSTO:ULTIO 29 3-1 Month Momentum % is N/A% as of Aug. 12, 2026. GuruFocus rates OSTO:ULTIO with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 1,386 Biotechnology companies, Zelluna ASA ranks worse than 53.82% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-12), Zelluna ASA's 3-1 Month Momentum % is N/A%.
The industry rank for Zelluna ASA's 3-1 Month Momentum % or its related term are showing as below:
OSTO:ULTIo's 3-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -7.05 * Ranked among companies with meaningful 3-1 Month Momentum % only.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Zelluna ASA 3-1 Month Momentum % Related Terms
OSTO:ULTIO vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Zelluna ASA's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zelluna ASA 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zelluna ASA's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Zelluna ASA's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zelluna ASA (OSTO:ULTIO) has a 3-1 Month Momentum % of N/A% as of Aug. 12, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Zelluna ASA and its competitors. According to the industry distribution chart, Zelluna ASA ranks #746 out of 1386 companies in the Biotechnology industry, placing it in the top 53.8%.
Is Zelluna ASA's 3-1 Month Momentum % too high?
Zelluna ASA's current 3-1 Month Momentum % is N/A%. Based on the distribution chart, Zelluna ASA ranks #746 out of 1386 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Zelluna ASA has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Zelluna ASA's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zelluna ASA ranks #746 out of 1386 companies for 3-1 Month Momentum %. This places Zelluna ASA in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Zelluna ASA and its competitors. Zelluna ASA's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelluna ASA stock overvalued right now?
Zelluna ASA (OSTO:ULTIO) has a current 3-1 Month Momentum % of N/A%. The current 3-1 Month Momentum % is N/A%. Zelluna ASA's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Zelluna ASA (OSTO:ULTIO), the current 3-1 Month Momentum % is N/A% as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zelluna ASA is a biotechnology company established to eliminate solid cancers by unleashing the powerful elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK). Its TCR-NK products are composed of healthy donor-derived NK cells that are genetically engineered to express a tumour-specific TCR that enable the TCR-NK cells to identify and eliminate cancer cells in the body of the patient. Its programme ZI-MA4-1, the first MAGE-A4-targeting TCR-NK therapy for solid tumours with high unmet medical need. Its other programmes include ZI-KL1-1, and ZI-PR-1.
29GF Score
Get the complete analysis for OSTO:ULTIO
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ULTIO has been successfully added to your 
